{"@id":"https://bioecon.ru/technology/mast-cell-targeted-therapeutics/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://bioecon.ru/technology/mast-cell-targeted-therapeutics/","json":"https://bioecon.ru/api/v1/technology/mast-cell-targeted-therapeutics/index.json"},"id":"mast-cell-targeted-therapeutics","industries":["pharma","biomanufacturing"],"lang":"ru","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/newlimit/","https://bioecon.ru/companies/altos-labs/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/cellmeat/","https://bioecon.ru/companies/esco-aster/","https://bioecon.ru/companies/astrazeneca/","https://bioecon.ru/companies/hlb-genex/","https://bioecon.ru/companies/simple-planet/","https://bioecon.ru/companies/integriculture/","https://bioecon.ru/companies/cryoport-systems/"]},"maturity":7,"name":"Таргетные терапевтические препараты против тучных клеток","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"Связывание ингибирующих рецепторов"},{"n":2,"title":"Подтверждение безопасности связывания"},{"n":3,"title":"Тесты апоптоза и дегрануляции"},{"n":4,"title":"Клиническая валидация"}],"summary":"Селективные препараты, направленно воздействующие на ингибирующие рецепторы тучных клеток (Siglec-8, MRGPRX2, Kit) для предотвращения дегрануляции или индукции апоптоза при аллергии.","url":"/technology/mast-cell-targeted-therapeutics/","verified":"2026-11-22"}